This may render FASN more widely suited biomarker for identifying glioma-derived EVs than tumor-specific antigens, such as EGFRvIII or IDH1-R132, which are only expressed in distinct subtypes and, as in the case of EGFRvIII, only by a subpopulation of tumor cells within malignant gliomas. The gene discussed is IDH1; the disease is glioma.